The design of nanovaccines capable of triggering effective antitumor immunity requires an
understanding of how the immune system senses and responds to threats, including …

The accumulation of tumor infiltrating lymphocytes (TILs) in ovarian cancer is prognostic for
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …

The T cell protein cytotoxic T lymphocyte antigen 4 (CTLA4) was identified as a crucial
negative regulator of the immune system over 15 years ago, but its mechanisms of action …

Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Background Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte
antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain …

Adoptive transfer of large numbers of tumor-reactive CD8+ cytotoxic T lymphocytes (CTLs)
expanded and differentiated in vitro has shown promising clinical activity against cancer …

Strategies to activate and rescue exhausted tumor-specific T cells, including the use of
monoclonal antibodies (mAb) that block the negative costimulatory receptors CTLA-4 and …

The human gut microbiota continues to demonstrate its importance in human health and
disease, largely owing to the countless number of studies investigating the fecal microbiota …

Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE)
associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter …

The immunotherapeutic agent ipilimumab has helped address a significant unmet need in
the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that …